UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8‑K
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report: March 12, 2018
(Date of earliest event reported)
BIOPHARMX CORPORATION
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
|
001-37411 |
|
59-3843182 |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
1505 Adams Drive, Suite D Menlo Park, California |
|
94025 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
(650) 889-5020
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8‑K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a‑12 under the Exchange Act (17 CFR 240.14a‑12) |
|
☐ |
Pre‑commencement communications pursuant to Rule 14d‑2(b) under the Exchange Act (17 CFR 240.14d‑2(b)) |
|
☐ |
Pre‑commencement communications pursuant to Rule 13e‑4(c) under the Exchange Act (17 CFR 240.13e‑4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
|
|
|
Emerging growth company |
☐ |
|
|
|
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. |
☐ |
||
Item 2.01 Results of Operations and Financial Condition
The information contained in Item 8.01 below regarding the cash and cash equivalents of BioPharmX Corporation (the “Company”) and its shares of common stock outstanding is incorporated herein by reference.
Item 8.01 Other Events
On March 12, 2018, the Company presented its updated corporate presentation at the 30th Annual ROTH Conference. In the corporate presentation, the Company disclosed that it held cash and cash equivalents of $7.6 million (unaudited) as of January 31, 2018. In addition, through March 9, 2018, the Company had received an additional $6.6 million (unaudited) in proceeds generated from warrant exercises subsequent to January 31, 2018. The Company also disclosed it had approximately 190.0 million shares of common stock outstanding (unaudited) as of March 9, 2018. These amounts reflect the Company’s estimates based solely upon information available to it as of the date of this Current Report on Form 8-K and have not been audited, reviewed or compiled by the Company’s independent registered public accounting firm.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
BIOPHARMX CORPORATION |
||
|
|
|
||
|
Date: March 12, 2018 |
By: |
/s/ Greg Kitchener |
|
|
|
|
Name: |
Greg Kitchener |
|
|
|
Title: |
Chief Financial Officer |